`
`Sent:
`
`To:
`
`cara lansden/cambridge/biogen;nsf;cara.lansden@biogenidec.com;smtp
`
`Wed Jun 14 2006 18:49:49 EDT
`
`gilmore o'neill/cambridge/biogen@biogenidec;minhua yang/cambridge/biogen@
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`lingamaneni/
`sarnelli/cambridge/biogen@biogenidec;
`
`Subject:
`
`Fw: BG12 MS IND
`
`To the BG-12 MS CDT:
`
`;ratna
`
`tammy
`
`The BG-12 MS IND is no longer on clinical hold!!! Thank you all for your hard work in turning
`around the response so quickly.
`
`Regards,
`Cara
`____________________________
`Cara Lansden
`Sr. Manager, Clinical Development
`Biogen Idec
`
`
`
`
`
`
`----- Forwarded by Cara Lansden/Cambridge/Biogen on 06/14/2006 06:45 PM -----
`
`Tammy Sarnelli/Cambridge/Biogen
`14-Jun-2006 04:23 PM
`Message Size: 2.0 KB
`
`To
`BG-12 Program Team,
`
`
`Subject
`BG12 MS IND
`
`
`
`
`
`Page 1 of 2
`
`Biogen Exhibit 2321
`Coalition v. Biogen
`IPR2015-01993
`
`
`
`Hello everyone:
`
`We were notified today by FDA that the clinical hold has been lifted! We are now free to begin
`the QTc study.
`
`Thank you to all of you who worked so hard to make the submission quickly.
`
`Sincerely
`Tammy
`
`Page 2 of 2
`
`